This suggests that PET/CT/MRI imaging with 2-[18F]BzAHA can be translated into clinical settings for selecting glioma patients who may benefit from SIRT1-targeted therapies and for monitoring the pharmacodynamics of SIRT1 inhibitors [46]. The gene discussed is SIRT1; the disease is central nervous system cancer.